The Pleasanton biotech turning a routine blood draw into clean, sequenceable DNA - on the bench, in the clinic, and in orbit.
Apostle Inc - Pleasanton, California. Company wordmark, apostlebio.com.
Everyone talks about detecting cancer from a vial of blood. Almost nobody talks about the step in between - pulling the faint genetic signal out of plasma without losing it. That step is the entire business of Apostle Inc.
Apostle Inc is a biotechnology company headquartered at 3589 Nevada Street in Pleasanton, California. It builds reagents, instruments, and services that isolate and preserve nucleic acids - especially circulating cell-free DNA (cfDNA) and cell-free RNA (cfRNA) - from blood and other body fluids.
Those cell-free fragments are a biological echo. A growing tumor, a developing fetus, or a circulating virus sheds tiny pieces of DNA and RNA into the bloodstream. Read them, and you can screen for cancer, run a non-invasive prenatal test, or track an infection - all from a standard blood draw rather than a surgical biopsy. The catch: the signal is small and easily contaminated, and the quality of everything downstream depends on how cleanly you extract it.
Apostle's answer is chemistry. Its flagship kit, Apostle MiniMax, uses proprietary magnetic nanoparticles - engineered with a specific surface chemistry and large surface area - to capture more cfDNA from plasma with less variation between runs. The beads grab the genetic material, a magnet pulls them out, contaminants wash away, and what remains is DNA clean enough for PCR, digital PCR, and next-generation sequencing.
The company spun out of Stanford's StartX accelerator in 2018 and has stayed deliberately small. With roughly 21 employees, it says its technologies have touched more than 20 million people and have been cited in journals including Nature Medicine, Cancer Cell, Nature Communications, Science Translational Medicine, and PNAS.
Figures compiled from company statements and public funding records; revenue estimated at roughly $4M annually.
“We seek to deliver the message of health to everyone on the earth and improve human lives, completely reshaping the global landscape of healthcare.”
- David Ge, MD, PhD, Co-Founder & CEOB2B model: reagent kits and instruments plus CLIA/CAP lab and CRO services.
Named a little like a superhero roster - the chemistry underneath is not.
High-efficiency magnetic-nanoparticle kit that extracts cell-free DNA and RNA from plasma, in manual or automated workflows, with high recovery and low variation.
Benchtop automation system that runs Apostle magnetic-bead chemistry for hands-off, high-throughput nucleic-acid isolation.
High-resolution DNA size-selection and short-fragment enrichment on the magnetic nano-platform.
Bioinformatics platform applying machine learning to cfDNA/cfRNA sequencing data for biomarker and mutation analysis.
Genomic DNA and RNA isolation kits spanning a range of specimen types.
CLIA-authorized, CAP-accredited laboratory offering cfDNA/cfRNA isolation and contract-research services.
In May 2025, npj Microgravity published the GENESTAR manual - the first standardized protocol for collecting astronaut biospecimens on U.S. commercial space missions, built from the Axiom-2 flight and led by Baylor College of Medicine's Human Genome Sequencing Center. Apostle MiniMax was designated the official method for cfDNA extraction.
Of 339 biospecimens collected under the manual, 98% of blood samples and 91.6% of non-blood samples passed quality control for omics assays - a hard bar to clear when your lab is in microgravity. It is an unusual credential for a 21-person company: the same bead chemistry sold to a Pleasanton research lab is now the standard for genomics in orbit.
Apostle plays in the sample-preparation layer of the genomics stack - the same neighborhood as extraction kits from QIAGEN (QIAamp), Thermo Fisher (MagMAX), Promega, and Norgen Biotek. Downstream sit the integrated liquid-biopsy diagnostics companies such as Guardant Health and GRAIL, which are customers-in-spirit more than direct rivals: they need exactly the clean cfDNA that Apostle's step produces.
Against the incumbents, Apostle's pitch is narrow and technical - a nanoparticle tuned specifically for cell-free DNA, with recovery and consistency that hold up across plasma volumes. That focus is why a global player like Beckman Coulter Life Sciences chose to enter an exclusive partnership around the MiniMax kit rather than build its own.
The other differentiator is credibility for its size. Apostle runs to ISO 13485 and ISO 9001 standards, holds CLIA authorization and CAP accreditation, and has seen its technology appear in FDA-authorized COVID-19 diagnostics. Regulated operations usually signal a much larger company; here they come bundled with a startup's headcount.
Its expertise is a rare crossover: nanomaterial chemistry from the co-founder bench, plus bioinformatics pedigree from CEO David Ge, who founded the bioinformatics group at Gilead Sciences. The company pairs the wet-lab kit with the Triton software layer, so extraction and analysis are designed to fit together.
About $9.2M raised in total - modest for a regulated biotech, and apparently intentional.
| Round | Amount | Date | Investors |
|---|---|---|---|
| Seed / VC | $2.3M | 2018 | Amino Capital, ShangBay Capital, Westlake Ventures, individuals |
| Series A | $3.3M | May 2019 | ShangBay Capital (lead) |
The founders reportedly sought $2M for their first round; investor interest pushed it to $2.3M.
David Ge, Bo Zhang and Xin Guo start Apostle and raise an initial ~$2.3M.
A $3.3M round led by ShangBay Capital funds the commercial launch of the MiniMax cfDNA kit.
Beckman Coulter Life Sciences enters an exclusive deal to distribute MiniMax for liquid-biopsy research.
Apostle stands up its own clinical and CRO laboratory to regulated standards.
Named the official cfDNA standard for astronaut biospecimen collection (GENESTAR / Axiom-2).
Cited across prenatal screening, colorectal and appendiceal cancer research, and infectious-disease control on multiple continents.
“We have listened to their ongoing challenges in working with cfDNA and sought to find ways to effectively combat those issues.”
- Steve Wowk, Director of Genomics, Beckman Coulter Life SciencesApostle develops kits, instruments, and services that isolate and preserve nucleic acids - especially circulating cell-free DNA and RNA - from blood, for liquid biopsy, cancer detection, prenatal testing, and infectious-disease research.
MiniMax is Apostle's flagship product: a magnetic nanoparticle-based kit that extracts cell-free DNA (and cfRNA) from plasma with high efficiency, low variation, and strong contaminant removal, in manual or automated workflows.
It was co-founded in 2018 by David Ge (CEO), Bo Zhang, and Xin Guo, and is headquartered in Pleasanton, California.
Apostle MiniMax was designated the official cfDNA extraction standard for astronaut biospecimen collection on U.S. commercial space missions, documented in the 2025 GENESTAR manual from the Axiom-2 mission.
Public sources report roughly $9.2M total, including an initial ~$2.3M round and a $3.3M Series A led by ShangBay Capital in May 2019.